Table 1.
Baseline characteristics of the first set.
| Clinicopathologic characteristics | Number of subjects (%) |
|---|---|
| Age | |
| <50 years | 251 (54.2) |
| ≥50 years | 212 (45.8) |
| Sex | |
| Male | 3 (0.6) |
| Female | 460 (99.4) |
| Histologic subtype | |
| Invasive ductal carcinoma, NOS | 398 (86) |
| Invasive lobular carcinoma | 21 (4.5) |
| Other subtypes | 44 (9.5) |
| pT stage | |
| pT1 | 198 (42.8) |
| pT2 | 238 (51.4) |
| pT3 | 19 (4.1) |
| pT4 | 8 (1.7) |
| Lymph node metastasis | |
| Absent | 251 (54.2) |
| Present | 212 (45.8) |
| Histologic grade* | |
| I | 80 (17.9) |
| II | 152 (34.1) |
| III | 214 (48.0) |
| Estrogen receptor | |
| Positive | 313 (67.6) |
| Negative | 150 (32.4) |
| Progesterone receptor | |
| Positive | 270 (58.3) |
| Negative | 193 (41.7) |
| Hormone receptor | |
| Positive | 323 (69.8) |
| Negative | 140 (30.2) |
| HER2 status | |
| Negative | 375 (81.0) |
| Positive | 88 (19.0) |
| p53 overexpression* | |
| Absent | 356 (77.1) |
| Present | 106 (22.9) |
| Ki-67 index | |
| <20% | 270 (58.3) |
| ≥20% | 193 (41.7) |
| Molecular subtype | |
| Luminal/HER2-negative subtype | 283 (61.1) |
| Luminal/HER2-postive subtype | 40 (8.6) |
| HER2-positive subtype | 48 (10.4) |
| Triple-negative subtype | 92 (19.9) |
| CEP17 copy number gain* | |
| Absent | 401 (87.2) |
| Present | 59 (12.8) |
*There are some missing data.